March 16, 2026
Headlines

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews

Sumain Faisal01 mins

Latest Ratings for NTLA

Date Firm Action From To
Mar 2022 Brookline Capital Upgrades Hold Buy
Mar 2022 Chardan Capital Maintains Buy
Feb 2022 William Blair Initiates Coverage On Outperform

View More Analyst Ratings for NTLA

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News